PMV Pharmaceuticals (PMVP) Total Current Liabilities (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Total Current Liabilities came in at $8.6 million in Q1 2026, down 11.93% YoY from $9.8 million in Q1 2025, and down 24.7% on a QoQ basis from $11.4 million in Q4 2025.
PMV Pharmaceuticals (PMVP) Total Current Liabilities (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 8 years of Total Current Liabilities data on file, last reported at $8.6 million in Q1 2026.
- Quarterly Total Current Liabilities fell 11.93% year-over-year to $8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.6 million (down 11.93% YoY) and the FY2025 annual result came in at $11.4 million, down 20.56% from the prior year.
- Total Current Liabilities declined to $8.6 million in Q1 2026, from $11.4 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $14.4 million in Q4 2024 to a low of $8.6 million in Q1 2026.
- A 5-year average of $11.6 million and a median of $11.4 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 101.6% — and 2025, when it retreated 20.56%.
- Tracing PMVP's Total Current Liabilities over 5 years: stood at $10.8 million in 2022, then gained by 29.51% to $14.0 million in 2023, then rose by 2.43% to $14.4 million in 2024, then dropped by 20.56% to $11.4 million in 2025, then dropped by 24.7% to $8.6 million in 2026.
- The last three Total Current Liabilities figures came in at $8.6 million (Q1 2026), $11.4 million (Q4 2025), and $12.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | PMV Pharmaceuticals | 70.74 Mn | -8.69 Mn | - | 10.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.60 Mn |
| Dec 31, 2025 | 11.42 Mn |
| Sep 30, 2025 | 12.30 Mn |
| Jun 30, 2025 | 11.61 Mn |
| Mar 31, 2025 | 9.76 Mn |
| Dec 31, 2024 | 14.37 Mn |
| Sep 30, 2024 | 13.56 Mn |
| Jun 30, 2024 | 11.39 Mn |
| Mar 31, 2024 | 12.06 Mn |
| Dec 31, 2023 | 14.03 Mn |
| Sep 30, 2023 | 10.72 Mn |
| Jun 30, 2023 | 11.45 Mn |
| Mar 31, 2023 | 10.59 Mn |
| Dec 31, 2022 | 10.83 Mn |
| Sep 30, 2022 | 11.66 Mn |
| Jun 30, 2022 | 11.38 Mn |
| Mar 31, 2022 | 11.69 Mn |
| Dec 31, 2021 | 12.22 Mn |
| Sep 30, 2021 | 8.56 Mn |
| Jun 30, 2021 | 7.50 Mn |